Ganitumab failure in pancreatic cancer another setback for Amgen/Takeda alliance
This article was originally published in Scrip
Executive Summary
Amgen and its Japanese development partner Takeda have halted the GAMMA Phase III multinational trial with ganitumab (AMG 479), after an interim analysis showed that the monoclonal antibody was likely to miss its overall survival primary endpoint in the pancreatic cancer study.